Halozyme (HALO) appoints Cortney Caudill Chief Operating Officer

Rhea-AI Filing Summary

Halozyme Therapeutics, Inc. reported a leadership change, appointing Cortney Caudill as Senior Vice President, Chief Operating Officer effective October 1, 2025. She previously served as the company’s Senior Vice President, Chief Operations Officer since October 2023 and has more than two decades of operational experience at multiple life sciences companies, including Aeglea Biotherapeutics and several global biotechnology and pharmaceutical organizations.

Ms. Caudill will receive an initial annual base salary of $600,000 and has a 2025 bonus target equal to 50% of her base salary under the company’s executive incentive plans. In connection with her appointment, she will receive an equity award valued at $500,000, split equally between stock options and restricted stock units, which will vest over four years under Halozyme’s standard vesting schedule. The company states there are no family relationships or related-party transactions involving Ms. Caudill in her new role.

FALSE000115903600011590362025-10-012025-10-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 1, 2025

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

________________________

Commission File Number 001-32335

Delaware						88-0488686
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)
12390 El Camino Real						92130
San Diego						(Zip Code)
California
(Address of principal executive offices)

(858) 794-8889

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

HALO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).         

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On October 1, 2025, Cortney Caudill was appointed as Senior Vice President, Chief Operating Officer of Halozyme Therapeutics, Inc. (the “Company”), effective immediately. Ms. Caudill (age 49) has served as the Company’s Senior Vice President, Chief Operations Officer since October 2023. Prior to joining the Company, from 2019 to October 2023, Ms. Caudill served in roles with increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and most recently as Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at various life sciences companies such as Cambrex Bioscience, Vaxagen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA. She received her B.S. degree in biology and her B.A degree in psychology from the University of Texas.

There are no family relationships between Ms. Caudill and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Ms. Caudill does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.

Ms. Caudill’s initial annual base salary as Chief Operating Officer will be $600,000 and she will be eligible to participate in the Company’s executive officer incentive plans, with a 2025 bonus target equal to 50% of her base salary. Ms. Caudill will be eligible to receive long-term incentive awards in accordance with the Compensation Committee’s equity award grant practices for the Company’s executive officers. In connection with her appointment as Chief Operating Officer, Ms. Caudill will receive an equity award valued at $500,000 delivered 50% in stock options and 50% in restricted stock units. The options and restricted stock units will vest in accordance with the Company’s standard four-year vesting schedule.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc. (Registrant)

Dated:

October 6, 2025

By:

/s/ Mark Snyder

Mark Snyder

Senior Vice President, General Counsel and Corporate Secretary

FAQ

What executive leadership change did Halozyme (HALO) disclose in this 8-K?

Halozyme Therapeutics, Inc. disclosed that Cortney Caudill was appointed Senior Vice President, Chief Operating Officer, effective October 1, 2025.

What is Cortney Caudill’s background before becoming COO at Halozyme (HALO)?

Ms. Caudill previously served as Halozyme’s Senior Vice President, Chief Operations Officer since October 2023 and held increasing responsibility roles at Aeglea Biotherapeutics from 2019 to 2023, as well as operational positions at several life sciences companies from 2002 to 2018.

What compensation will Halozyme (HALO) pay its new COO, Cortney Caudill?

Ms. Caudill’s initial annual base salary as Chief Operating Officer is $600,000, and she has a 2025 bonus target equal to 50% of her base salary under Halozyme’s executive incentive plans.

What equity award is Halozyme (HALO) granting to the new COO?

In connection with her appointment, Ms. Caudill will receive an equity award valued at $500,000, delivered 50% in stock options and 50% in restricted stock units, vesting under Halozyme’s standard four-year schedule.

Are there any related-party or family relationships disclosed for Halozyme’s new COO?

Halozyme states there are no family relationships between Ms. Caudill and any director, executive officer, or person chosen to become one, and she does not have a direct or indirect material interest in any company transaction or arrangement.

Does the Halozyme (HALO) 8-K mention Ms. Caudill’s education?

Yes. The filing notes that Ms. Caudill received a B.S. in biology and a B.A. in psychology from the University of Texas.